Catalent

Global, cGMP Micronizing and Milling for the Pharmaceutical Industry

14 Schoolhouse Road, Somerset, NJ 08873, United States of America



Support new drug proposals

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.

With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents.

Catalent has helped innovators ranging from small start-ups to Fortune 5 Pharma companies by optimizing and manufacturing thousands of pharmaceutical, biologic, consumer health and beauty products.

Contact us today to see how we can help you get your product to market faster.

Development expertise

With extensive early phase development expertise in analytics, biologics, pre-formulation and formulation, we can help you achieve faster more efficient development timelines to produce better products.

  • In pharmaceuticals we provide expert guidance, pre-screen solubility assessments for drugability, a best-in class API optimization platform, and a wide array of the most up-to-date bioavailability enhancement tools, including particle size reduction, spray drying, hot melt extrusion, and lipid based drug delivery systems.
  • In biologics, we help accelerate you to clinic and beyond with GPEx® technology to generate stable, high-performance cell lines.
  • In consumer health, we help you deliver innovative products backed by an extensive product library to help get you on the market faster.

Advanced Delivery Technologies

Our innovative dose forms and advanced manufacturing technologies can help you to create better products and therapeutic outcomes to improve the lives of patients and consumers. Our superior enabling formulation technologies can help you meet your target product profile, improve value, and achieve better outcomes, including:

  • RP Scherer Softgel Delivery Technologies
  • Zydis® Fast Dissolve Delivery Technology
  • Advasept® glass-free injectable technology
  • SMARTag® antibody drug conjugate technology

Getting product to the market

Whether it’s managing your clinical supply needs or commercially manufacturing your products, we have a solution for you.

  • Our clinical supply services can help you manage your local, regional, or global studies, including special handling capabilities and comparator sourcing services.
  • Our flexible manufacturing solutions can help you scale up and get to market with tailored solutions and special handling capabilities, all backed by discipline, rigor, and rhythm that has resulted in a reliable global network that will supply your product to the highest quality standards on time.

Flexible Manufacturing

Safinamide is the first new molecule in 20 years to be used in the treatment of Parkinson's.

Early Stage Oral Development

The goal of pre-formulation is to establish the physical, chemical, and mechanical properties of a drug substance that provides a roadmap and a guide for how to formulate the molecule into a fit-for-purpose formulation.

RP Scherer Softgel Technologies

An innovative biotechnology company exploring novel therapeutics for neuroscience indications had developed a promising new chemical entity for the treatment of a severe paediatric genetic disease.

Case Study: Innovative Clinical Supply Solutions

With Catalent's team of packaging experts and extensive cold chain capabilities, this case study discusses the creation of a custom packaging and distribution solution to meet this client’s unique needs.

Catalent to Discuss how Drug Design Influences Patient Outcomes at PODD

Catalent, a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products, announced it will present at the 9th Partnership Opportunities in Drug Delivery (PODD) annual conference at the Renaissance Boston Waterfront Hotel, Boston on 7-8 October 2019.

Catalent to Discuss New Technologies at The Pharma Forum

Catalent, a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products, announced that Alex Haig, Senior Director, Engineering will present at the Pharma Forum at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on 18-19 September 2019.

Catalent to Present at East Conference on September 9-12 2019

Catalent, a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Steve Hager, PhD, Senior Director, Technical Support will present at the BioProcess International (BPI) East Conference at the Boston Convention and Exhibition Center, Boston, on 9-12 September.

The Use Of Continuous Chromatography In Effective Process Design Presentation

Catalent, a leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, has announced that Ben Kester, Manager and Senior Scientist, Purification Development, Catalent Biologics, will present at the upcoming 32nd International Symposium on Preparative and Process Chromatography (PREP Symposium) at the Hyatt Regency Baltimore Inner Harbor, Baltimore, Maryland on 7-10 July 2019.

Clinical Packaging Capabilities Expansion in Shanghai, China

Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announces that work to expand its primary packaging capabilities at its clinical facility in Shanghai, China has reached the commissioning stage, with a scheduled completion date of 2018.

Catalent to Manufacture Opiod Discontinuation Treatment Iofexidine

Catalent Pharma Solutions has announced it has entered an exclusive agreement with US WorldMeds for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment.

Catalent Broadens Scope of OptiForm Solution Suite

Catalent Pharma Solutions has announced it has broadened the scope of its multi-award winning OptiForm® Solution Suite platform to provide an efficient and seamless path from late-stage discovery to Phase I clinical trials.

Catalent Expands Kansas City Facility to Meet Demand

Catalent Pharma Solutions has announced it has completed an expansion project at its Kansas City facility to significantly increase controlled-temperature storage capabilities for its clinical supply business.

Catalent Acquires Accucaps to Expand Softigel Development and Manufacturing

Global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products Catalent has announced that the company has agreed to acquire Accucaps Industries, the Canada-based developer and manufacturer of over-the-counter (OTC), high-potency, and conventional pharmaceutical softgels.

Catalent

14 Schoolhouse Road

Somerset, NJ 08873

United States of America

+1 732 537 6200 +1 610 251 7400 www.catalent.com Development Delivery Supply Catalent Biologics Consumer Health Animal Health
Catalent

2125 Ambassador Drive

Windsor, N9C 3R5

Ontario

United States of America

+1 800 665 7210
Catalent

Avenida Jerome Case, 1277,

Sorocaba, SP, 18087-220

Brazil

+55 15 3235 3513
Catalent

399 Chengnan Rd

Haining,

Zhejiang 314408

China

+86 573 8741 2028
Catalent

1656 Kurami,

Kakegawa.shi,

Shizuoka 436-0341,

Japan

+81 537 29 1131